File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Correction of anemia using self-administered daily subcutaneous erythropoietin in uremic patients on continuous ambulatory peritoneal dialysis

TitleCorrection of anemia using self-administered daily subcutaneous erythropoietin in uremic patients on continuous ambulatory peritoneal dialysis
Authors
Issue Date1993
PublisherWichtig Editore srl. The Journal's web site is located at http://www.artificial-organs.com
Citation
International Journal Of Artificial Organs, 1993, v. 16 n. 7, p. 510-514 How to Cite?
AbstractWe studied the effects of self-administered, daily, low-dose, subcutaneous (SC) erythropoietin (EPO) therapy in 15 uremic patients on continuous ambulatory peritoneal dialysis (CAPD) for 16 weeks to assess its efficacy and safety. The patients had baseline hemoglobin (Hb) levels of <8 g/dl and were started on 10 u/kg/day of beta-EPO. The dosage of EPO was adjusted every 4 weeks according to hematological response. The patients learned to inject into their thighs themselves. Hb increased significantly from 6.6 ± 0.2 g/dl (mean ± SEM) at week 0 to 9.0 ± 0.3 at week 8 and 10.0 ± 0.4 at week 16 (p < 0.0001). Hematocrit (Hct) increased significantly from 0.20 ± 0.01 at week 0 to 0.27 ± 0.01 at week 8 and 0.29 ± 0.001 at week 16 (p < 0.0001). The mean EPO dose was 10 u/kg/day at week 0 and 10.5 ± 0.4 at week 8 and 10.3 ± 0.5 at week 16. After minor adjustments in antihypertensive therapy had been made no significant differences in mean arterial blood pressure were noted. Six of 15 patients required increased dosage of antihypertensive drugs. All patients were given oral iron supplements. There was a significant decrease in percentage of transferrin saturation and 10 patients required additional intravenous iron supplements. There was no significant difference in the serum levels of creatinine, albumin, potassium, phosphate and urate with EPO treatment. There were no local complications at the sites of injection and the injections themselves were quite painless. We conclude that low-dose SC daily EPO is effective and safe in the correction of anemia in CAPD patients.
Persistent Identifierhttp://hdl.handle.net/10722/161975
ISSN
2015 Impact Factor: 1.005
2015 SCImago Journal Rankings: 0.585
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLi, PKTen_HK
dc.contributor.authorLeung, CBen_HK
dc.contributor.authorLui, SFen_HK
dc.contributor.authorLeung, JCKen_HK
dc.contributor.authorShek, ACCen_HK
dc.contributor.authorLai, KNen_HK
dc.date.accessioned2012-09-05T05:16:25Z-
dc.date.available2012-09-05T05:16:25Z-
dc.date.issued1993en_HK
dc.identifier.citationInternational Journal Of Artificial Organs, 1993, v. 16 n. 7, p. 510-514en_HK
dc.identifier.issn0391-3988en_HK
dc.identifier.urihttp://hdl.handle.net/10722/161975-
dc.description.abstractWe studied the effects of self-administered, daily, low-dose, subcutaneous (SC) erythropoietin (EPO) therapy in 15 uremic patients on continuous ambulatory peritoneal dialysis (CAPD) for 16 weeks to assess its efficacy and safety. The patients had baseline hemoglobin (Hb) levels of <8 g/dl and were started on 10 u/kg/day of beta-EPO. The dosage of EPO was adjusted every 4 weeks according to hematological response. The patients learned to inject into their thighs themselves. Hb increased significantly from 6.6 ± 0.2 g/dl (mean ± SEM) at week 0 to 9.0 ± 0.3 at week 8 and 10.0 ± 0.4 at week 16 (p < 0.0001). Hematocrit (Hct) increased significantly from 0.20 ± 0.01 at week 0 to 0.27 ± 0.01 at week 8 and 0.29 ± 0.001 at week 16 (p < 0.0001). The mean EPO dose was 10 u/kg/day at week 0 and 10.5 ± 0.4 at week 8 and 10.3 ± 0.5 at week 16. After minor adjustments in antihypertensive therapy had been made no significant differences in mean arterial blood pressure were noted. Six of 15 patients required increased dosage of antihypertensive drugs. All patients were given oral iron supplements. There was a significant decrease in percentage of transferrin saturation and 10 patients required additional intravenous iron supplements. There was no significant difference in the serum levels of creatinine, albumin, potassium, phosphate and urate with EPO treatment. There were no local complications at the sites of injection and the injections themselves were quite painless. We conclude that low-dose SC daily EPO is effective and safe in the correction of anemia in CAPD patients.en_HK
dc.languageengen_US
dc.publisherWichtig Editore srl. The Journal's web site is located at http://www.artificial-organs.comen_HK
dc.relation.ispartofInternational Journal of Artificial Organsen_HK
dc.subject.meshAdulten_US
dc.subject.meshAnemia - Drug Therapy - Etiologyen_US
dc.subject.meshDrug Administration Scheduleen_US
dc.subject.meshErythropoietin - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshHemoglobins - Analysisen_US
dc.subject.meshHumansen_US
dc.subject.meshInjections, Subcutaneousen_US
dc.subject.meshMaleen_US
dc.subject.meshPeritoneal Dialysis, Continuous Ambulatoryen_US
dc.subject.meshRecombinant Proteins - Administration & Dosage - Therapeutic Useen_US
dc.subject.meshSelf Administrationen_US
dc.subject.meshUremia - Complications - Therapyen_US
dc.titleCorrection of anemia using self-administered daily subcutaneous erythropoietin in uremic patients on continuous ambulatory peritoneal dialysisen_HK
dc.typeArticleen_HK
dc.identifier.emailLeung, JCK: jckleung@hku.hken_HK
dc.identifier.emailLai, KN: knlai@hku.hken_HK
dc.identifier.authorityLeung, JCK=rp00448en_HK
dc.identifier.authorityLai, KN=rp00324en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid8370605-
dc.identifier.scopuseid_2-s2.0-0027249925en_HK
dc.identifier.volume16en_HK
dc.identifier.issue7en_HK
dc.identifier.spage510en_HK
dc.identifier.epage514en_HK
dc.identifier.isiWOS:A1993LQ45900003-
dc.publisher.placeItalyen_HK
dc.identifier.scopusauthoridLi, PKT=25928016800en_HK
dc.identifier.scopusauthoridLeung, CB=16750769500en_HK
dc.identifier.scopusauthoridLui, SF=7102379144en_HK
dc.identifier.scopusauthoridLeung, JCK=7202180349en_HK
dc.identifier.scopusauthoridShek, ACC=6602843306en_HK
dc.identifier.scopusauthoridLai, KN=7402135706en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats